% | $
Quotes you view appear here for quick access.

Sinovac Biotech Ltd. Message Board

  • z101789 z101789 Apr 15, 2013 2:49 PM Flag

    Bird flu drug Inavir, in phase II trials in the US by BOTA

    MELBOURNE, Australia--(BUSINESS WIRE)-- Biota Holdings Limited (ASX:BTA) today announced that Daiichi Sankyo has received approval to manufacture and market Inavir® (pronounced in-a-veer) in Japan. Inavir® is Daiichi Sankyo’s brand of laninamivir octanoate and also previously known as CS-8958. The approved indication is for the treatment of influenza in adults and children.

    Inavir® (laninamivir octanoate), is the first drug of a new class of long acting neuraminidase inhibitors (LANIs) to address the limitation of the current products, which require daily or more frequent dosing. Neuraminidase inhibitors (NIs) are antiviral agents effective against influenza, providing both for the treatment of an established influenza infection or for the prevention of influenza prior to exposure. NIs are antiviral medicines and are not vaccines.

    The new class of long acting neuraminidase inhibitors provide the opportunity to medicate patients on a “one and done” basis and offer a number of potential benefits. These include that the patient is more likely to use the product properly and as intended and also offers a reduced cost of storage and transport per course, where the product is intended to be stockpiled.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
5.92+0.01(+0.17%)Jun 28 3:59 PMEDT